コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ibility of gene therapy for the treatment of esophageal ulcers.
2 ion is important for healing of experimental esophageal ulcers.
6 e associated with cytomegalovirus-associated esophageal ulcers and probably contribute to the inflamm
7 erosive esophagitis, Barrett's esophagus, or esophageal ulcer), and pH impedance testing on PPI thera
8 c biopsy of their cytomegalovirus-associated esophageal ulcers before and after ganciclovir therapy.
9 eatment with celecoxib significantly delayed esophageal ulcer healing and suppressed ulceration-trigg
10 the COX-2 selective inhibitor, celecoxib, on esophageal ulcer healing as well as on the cellular and
11 hese findings indicate that celecoxib delays esophageal ulcer healing by reducing ulceration-induced
14 n essential role of VEGF and angiogenesis in esophageal ulcer healing, and 3) demonstrate the feasibi
15 termine the efficacy of VEGF gene therapy in esophageal ulcer healing, we studied whether a single lo
17 issue destruction associated with idiopathic esophageal ulcers (IEUs) poses a diagnostic and therapeu
19 the endoscopic finding of a longitudinal mid-esophageal ulcer in the presence of proximal stricture m
20 ities in presentation and treatment to giant esophageal ulcers in human immunodeficiency virus infect
23 ment, and postablation endoscopy documenting esophageal ulcer may identify patients at higher risk fo
24 ith a history of severe erosive esophagitis, esophageal ulcer, or peptic stricture, should generally